Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: Validation of safe corrections for antipsychotic polypharmacy and the high-dose method

International Journal of Neuropsychopharmacology

Volumn 18, Issue 5, 2015, Pages 1-8

  Yamanouchi, Yoshio ^a   Sukegawa, Tsuruhei ^b   Inagaki, Ataru ^c   Inada, Toshiya ^d   Yoshio, Takashi ^e   Yoshimura, Reiji ^f   Iwata, Nakao ^g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c AOYAMA GAKUIN UNIVERSITY   (Japan)

^d SEIWA HOSPITAL   (Japan)

^e TOHO UNIVERSITY   (Japan)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; Clinical Trial; Polypharmacy; Psychopharmacology; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CATATONIC SCHIZOPHRENIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; ELECTROCARDIOGRAPHY; FEMALE; HEBEPHRENIA; HUMAN; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL STRESS; MULTICENTER STUDY; OPEN STUDY; PARANOID SCHIZOPHRENIA; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; TREATMENT DURATION; ADULT; CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; PSYCHOPHARMACOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYPHARMACY; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84931274260     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu016     Document Type: Article

References (29)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th ed text rev (DSM-IV-TR). Washington: American Psychiatric Association.
2. Atkinson M, Zibin S, Chuang H (1997) Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am J Psychiatry 154:99-105.
3. Barnes TRE, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25:383-399.
4. Collell CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35:443-457.
5. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, Schizophrenia Trials Network (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702-708.
6. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
7. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV axis I disorders. Biometrics Research Department, Colombia University, NY [Japanese translation/rights arranged with First M.B. though Japan UNI Agency, Inc., Tokyo].
8. Fleischhacker WW, Uchida H (2014) Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 17:1083-1093.
9. Goh YL, Seng KH, Chuan ASH, Chua HC (2011) Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia. Perm J 15:52-56.
10. Guy W (2000) Clinical Global Impressions (CGI) Scale. Modified from: Rush J, et al.: Psychiatric Measures. Washington DC: American Psychiatric Association.
11. Inada T (2009) DIEPSS: a second-generation rating scale for antipsychotic- induced extrapyramidal symptoms: drug-induced Extrapyramidal Symptoms Scale [in Japanese]. Tokyo: Seiwa Shoten Publishers, Inc.
12. Inagaki A, Inada T (2008) Calculation of the equivalent doses of new antipsychotics (V) [in Japanese]. Blonanserin Jpn J Clin Psychopharmacol 5:887-890.
13. Ito H, Okumura Y, Higuchi T, Tan CH, Shinfuku N (2012) International variation in antipsychotic prescribing for schizophrenia: pooled results from the research on East Asia psychotropic prescription (reap) studies. Open J Psychiatr 2:340-346.
14. Kang M, Ragan BG, Park JH (2008) Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train 43:215-221.
15. Lingjaerede O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:11-100.
16. Manchanda R, Saupe R, Hirsch SR (1986) Comparison between the Brief Psychiatric Rating Scale and the Manchester Scale for the rating of schizophrenic symptoms. Acta Psychiatr Scand 74:563-568.
17. Miodownik C, Lerner V, Kibari A, Toder D, Cohen H (2006) The effect of sudden clozapine discontinuation of management of schizophrenic patients: a retrospective controlled study. J Clin Psychiatry 67:1204-1208.
18. Mizumoto A, Takeuchi O (2010) Primer of effect size and statistical power [in Japanese]. LET Kansai Chapter Collected Papers. 47-73.
19. Murasugi K, Hagiwara T, Shouda S (2004) Attempt to correct antipsychotic administration to monotherapy and dose reduction for chronic schizophrenia patients. Development of the treatment and rehabilitation guideline for schizophrenia and the demonstration study of its effectiveness: Final Report of the National Project Team, supported by the research grant for nervous and mental disorders from the Ministry of Health, Labour and Welfare, Japan in 2001, pp67-73. Tokyo: Ministry Health, Labour and Welfare in Japan. [in Japanese].
20. Okumura Y, Noda T, Ito H (2013) Antipsychotics prescribing patterns of with schizophrenia in Japan: using the national database of health insurance claim information and specified medical checkups [in Japanese]. Jpn J Clin Psychopharmacol 16:1201-1215.
21. Samaha AN (2013) Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 52:9-16.
22. Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, Iwata N (2014) Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry 14:103.
23. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H (2004) Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7:133-142.
24. Takekawa Y, Hori A, Tsunashima K (1994) Reliability and validity of Japanese version of Manchester Scale [in Japanese]. Seishinigaku 36:389-394.
25. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M (2012) Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res 143:215-220.
26. Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, Sipos A, Harrison G (2008) The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards: a cluster randomized controlled trial. Psychol Med 38:705-715.
27. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M (2002) Estimating an EQ-5D population value set: the case of Japan. Health Econ 11:341-353.
28. Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N (2012) Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry 45:7-12.
29. Yoshio T, Inada T, Uno J, Miwa T, Kitagawa K, Miyahara Y, Umeda K, Kato T, Inagaki A, Nabeshima T (2012) Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol 27:70-75.